Education
About Us
Working with TipRanks
Follow Us
Cerus Corp (CERS)
NASDAQ:CERS
CERS Stock Chart & Stats
$2.09
-$0.02(-1.22%)
At close: 4:00 PM EST
$2.09
-$0.02(-1.22%)
Day’s Range― - ―
52-Week Range$1.12 - $2.26
Previous CloseN/A
Volume302.69K
Average Volume (3M)1.33M
Market Cap
$401.46M
Enterprise Value$325.42M
Total Cash (Recent Filing)$78.51M
Total Debt (Recent Filing)$98.19M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Feb 19, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding192,087,500
10 Day Avg. Volume873,312
30 Day Avg. Volume1,326,499
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.06
Price to Sales (P/S)1.58
P/FCF Ratio33.35
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit2.96
Enterprise Value/Ebitda-55.42
Forecast
1Y Price Target
$4.50Price Target Upside115.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Distribution And PartnershipsAnalyst notes the group purchasing agreement with Blood Centers of America extends national access to the product line and leverages established logistics to accelerate hospital uptake.
Market Share Expansion - INTERCEPT PlateletsAnalyst points out growing U.S. traction for INTERCEPT platelets driven by easier use, extended shelf life, and reduced wastage, supporting continued market share gains.
Product Adoption - Intercept FibrinogenAnalyst highlights rapid adoption of the Intercept fibrinogen product as it shifts sales toward kit-based production at blood centers, improving accessibility and creating a scalable revenue stream.
Bears Say
Regulatory Timing RiskAnalyst warns that delays in the European review process for INTERCEPT red blood cells have pushed a key approval milestone out, dampening near-term growth expectations.
Segment Penetration RiskAnalyst notes relatively low penetration within independent blood centers, creating downside risk if expansion efforts into this important channel do not succeed.
Share Price WeaknessAnalyst highlights that shares have lagged peers and trade near a 52-week low, which could weigh on investor sentiment and limit financing flexibility.
Cerus News
CERS FAQ
What was Cerus Corp’s price range in the past 12 months?
Cerus Corp lowest stock price was $1.12 and its highest was $2.26 in the past 12 months.
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is $401.46M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Feb 19, 2026 which is in 37 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.028.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is >-0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 192,087,500 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of $0 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 21.277%.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in CERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (115.31% Upside)
$4.50 (115.31% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $93.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.22%
12-Months-Change
Fundamentals
Return on Equity
-27.77%
Trailing 12-Months
Asset Growth
13.53%
Trailing 12-Months
Company Description
Cerus Corp
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
CERS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cerus Corporation's earnings call for Q3 2025 highlighted significant revenue growth and positive financial performance, driven by strong demand for INTERCEPT products and successful international expansion efforts. However, the company faces challenges with gross margin pressures and regulatory delays in Europe. Despite these hurdles, the overall outlook remains optimistic with raised revenue guidance and continued focus on operational execution.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$4.50
▲(115.31% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
4.87% Insiders
13.53% Mutual Funds
32.96% Other Institutional Investors
28.82% Public Companies and
Individual Investors